TAP was downregulated using an siRNA that was targeted to tumor cells in mice by conjugation to a nucleolin (Nucl)-binding oligonucleotide aptamer, a broad-spectrum tumor targeting ligand [13], and vaccinated against the induced TAP TEIPP by targeted delivery of the TAP siRNA to resident dendritic cells using a short Toll-like receptor 9 (TLR9) binding CpG containing oligonucleotide. This evidence concerns the gene TLR9 and neoplasm.